Skip to main content
. Author manuscript; available in PMC: 2020 Sep 16.
Published in final edited form as: Cancer Cell. 2019 Aug 29;36(3):218–235. doi: 10.1016/j.ccell.2019.07.010

Figure 7. Targetable Vulnerabilities of aPKC-Deficient Tumors.

Figure 7.

TGFβ inhibition with Galunisertib combined with anti PD-L1 antibodies (Ab) exploits a vulnerability created in highly mesenchymal CRC, like those from the serrated origin, by alleviating the stromal activation and boosting the antitumor response. Also, inhibition of PHGDH and/or DNMT activity with azacytidine (aza) can exploit a vulnerability created in therapy-resistant PCa to block NEPC differentiation and tumorigenesis.